Virend topical SP-303 data

Results of a Phase II double-blind, placebo-controlled trial in 45 patients showed that 38 percent of 24 treated patients had lesions that healed completely after the topical drug was applied three times daily for three weeks, compared to 14 percent of the 21 patients applying placebo.

Seventeen patients chose to continue treatment after the study ended, eight of whom were using placebo. Eight of the 17 were completely healed. ...